[sammyboyfor]

NuCare Clinics is the first clinic in New Zealand to offer Acoustic Wave Therapy (AWT) to treat Erectile Dysfunction (ED).
Acoustic Wave therapy is:

SAFE

A SAFE procedure proven in over 100 research studies using AWT for erectile dysfunction specifically

PAINLESS

A PAINLESS procedure. No injections, no local anaesthetic is required, is not at all painful and only the vibration effect from the sound waves is felt during the treatment.

NATURAL

A 100% NATURAL therapy without the need for using medications, blue pills, or injections. It is sound waves delivered at a special rate and amount that stimulates the development of new blood vessels and stem cells within the penis to rejuvenate the tissues and significantly improve erectile function

TWICE a week for 3 WEEKS

Twice a week for 3 weeks is all it takes to complete the standard treatment.



At NUCARE we use the treatment protocol developed by Dr Igor Motil, a Urologist who has specialised in successfully treating man men who have declining erectile function with Acoustic Wave Therapy.

This protocol has been shown in research studies to be effective in 80% of men (Motil, I & Sramkova, T. (2017). ED treatment by low intensity focused shock waves - a comparison of available devices and therapeutic techniques. The Journal of Sexual Medicine. 13:S116)



Call the Registered Nurse now on 0800 NUCARE or email your contact details to discuss in confidence your erectile dysfunction problems and concerns and find out more about Acoustic Wave Therapy.


Two systematic reviews, which are a rigorous methods of analysing multiple research studies to form a conclusion, were published this year (2017). The conclusion of the research study of the European Urology journal of 833 patients was:

"These studies suggest that LI-ESWT could significantly improve the IIEF (International Index of Erectile Function) and EHS (Erection Hardness Score) of Erectile Dysfunction” (Lu, et al 2017)



The conclusion of of the research study of the Journal of Sexual Medicine of 602 participants was: "In this meta-analysis of seven randomized controlled trials, treatment of ED with LI-ESWT resulted in a significant increase in IIEF-EF scores." (Clavijo, et al 2017).



"LI-ESWT is well known among experts in sexual medicine and the treatment is perceived as safe and effective against vasculogenic ED" (Fode et al 2017).



If untreated, erectile dysfunction will not go away!
Erectile dysfunction (ED) is simply the repeated inability to get or to keep an erection firm enough for sexual intercourse.

You might find that you can’t get an erection at all, or you can get one only sometimes or you can only keep an erection for a brief period of time.

Some people believe that Erectile Dysfunction is just a part of getting older – it’s not. It’s caused by a physical or psychological problem that can be treated. And because it’s such a personal issue, you might feel awkward about seeking help but don’t worry: Erectile Dysfunction is very, very common and is very treatable and many cases.



The registered Nurses at NuCare Clinics have been trained to evaluate your erectile function. The nurses discuss erectile function with lots of men every week and successfully treat the vast majority of them with Acoustic Wave Therapy.





Linear focused Acoustic Wave Therapy for vascular Erectile Dysfunction



Acoustic waves are often referred to as "shockwaves" or "shock wave" in medical articles.

This is not because it is using a shock like an electrical shock but rather the phenomenon in Physics is described as an acoustic shock wave.

Similar to when a stone is thrown into a pond, the ripples moving outwards are shock waves.

These are similar to the shockwaves of Acoustic Wave Therapy.




The LSTC-ED (Linear Acoustic wave Tissue Coverage) treatment - a new and unique approach
Point focused and linear focused shockwaves have shown to provide good results in the treatment of vascular-related Erectile dysfunction. However they were hindered by difficulty in treatment delivery and especially treatment coverage using specialised applicators.




New experience in the low intensity shockwave treatment of ED using a therapy source with a linear shaped therapy focus are showing improved results utilizing an optimized, new treatment strategy. The treatment strategy is called LSTC-ED (Linear Shockwave Tissue Coverage - Erectile Dysfunction).

The innovation in treatment involves the direction of the energy application and the course of treatment which covers across the entire cavernous bodies. The energy is applied at a right angle to the cavernous bodies by moving the therapy source longitudinally through the Penis (Corpora Cavernosa) and Perineum (Crura Penis), ensuring that the optimised energy is delivered through the entire target tissue.



We have used the utmost care in researching and clinical approval of this method. A reputable evidence and study proof was important to us. A prospective, multicenter placebo-controlled study with 75 patients is showing a significant improvement in IIEF-5 scores and a successful treatment in 81% of patients after one month of treatment.

A functional improvement was proven 6 months after treatment and underlined the long-term effect of LSTC ED treatment.

The main mechanism of action in ED treatment with Acoustic Waves:

- Neovascularisation - formation of new blood vessels
- Improved blood circulation

Prevalence of Erectile Dysfunction
Research studies published in peer-reviewed journals reveal some interesting facts about the incidence and prevalence of erectile dysfunction as well as the severity affecting these men. A summary of the findings of the various studies is provided with the primary author of each study mentioned. There are hyperlinks provided to the abstract of the research studies for further reading and research.



Take home point: Increasing incidence of erectile function ranging in ages from 18-100. Only 10% of men seek help and of those 10%, only 9% had received treatment.



DO NOT DELAY TREATMENT. ED will not go away.



Call the Nurse at NUCARE clinics on 0800 NUCARE and discuss your options for effective natural therapy for erectile dysfunction



Summary of research on the prevalence of Erectile Dysfunction


Mutha, 2015: 41% of men with erectile dysfunction were from the age group of 30-39 years.



Martins, 2010: Prevalence of ED in men 18-40 years old was 35.0% (73.7% mild, 26.3% moderate/complete).



Rhoden 2002: The prevalence of all degrees of ED was estimated as 53.9%.

In this group of men, the degree of ED was mild in 21.5%, mild to moderate in 14.1%, moderate in 6.3%, and severe in 11.9%.

According to age groups, the rates of ED were:

40-49 years (36.4%)

50-59 year (42.5%)

60-69 year (58.1%)

70-79 years (79.4%)

over 80 years (100%)



Abdo, 2006: The overall prevalence of ED was 45.1% (31.2% mild, 12.2% moderate)



Lyngdorf, 2004: Only 10% of the men with sexual problems seek advice and only 9% suffering from ED had received some kind of treatment.



Frederick, 2014: In a large group of men (6,228,509) >/=30 years in a commercial medical insurance dataset with a diagnosis code for ED during 12-month period only 25.4% of 6,2 million men with ED were treated during study period. Despite HIGH prevalence of ED with age, most men continue receiving NO TREATMENT.



In a study by Wang, 2016, the pooled prevalence of ED in men was 49.69%

The occurrence rates of ED by age groups were:

younger than 30: 20.86%,
30 to 39: 25.30%
40 to 49: 40.48%
50 to 59: 60.12%
60 to 69: 79.10%
70 years: 93.72%
The severity-specific prevalences of ED were:

Mild: 32.54%
Moderate: 9.86%
Severe: 13.97%
ED prevalences reported by different diagnostic methods were:

Self-reports: 14.19%
Chinese Index of Erectile Function: 44.60%
International Index of Erectile Function-5: 49.91% (Wang, 2016).


It has been reported that there is a worldwide increase in erectile dysfunction. The prevalence of approximately 322 million with ED, an increase of nearly 170 million men since 1995 (Ayta, 1999).



Ansong, 2000: The overall prevalence of ED was 46.3% (50-76 years) while the minimum prevalence was estimated as 21.3%.

Age-specific prevalence was:

50-54 years: 26.0%

55-59 years: 34.9%

60-64 years: 46.9%

65-69 years: 57.8%

70-76 years: 69.4%